本文已被:浏览 972次 下载 292次 |
码上扫一扫! |
|
一线RCHOP方案治疗不同组织学亚型滤泡性淋巴瘤3级患者的临床疗效 |
陈菲菲1, 阿孜古丽·麦合麦提1,2, 魏征1, 承璐雅1, 王伟光1, 庄静丽1, 袁玲1, 程志祥1, 王志梅1, 季丽莉1, 葛晓雯3, 刘澎1
|
1.复旦大学附属中山医院血液科, 上海 200032;2.新疆医科大学附属肿瘤医院淋巴瘤科, 乌鲁木齐 830000;3.复旦大学附属中山医院病理科, 上海 200032
|
|
摘要: |
目的: 探讨一线RCHOP方案治疗不同组织学亚型滤泡性淋巴瘤(follicular lymphoma,FL)3级患者患者的临床疗效。方法: 回顾性分析2009年1月至2019年12月复旦大学附属中山医院收治的初诊并予一线RCHOP方案治疗的61例FL 3级患者的临床资料。患者分为FL 3A级组(n=42)和侵袭性FL组(n=19),侵袭性FL组包括3A级合并3B级2例、3B级8例和FL 3级伴弥漫大B细胞淋巴瘤成分9例。结果: 两组患者性别、年龄、β2微球蛋白水平、乳酸脱氢酶水平、AnnArbor分期、B组症状、骨髓受累等差异均无统计学意义。中位随访时间为40.2个月。2组患者的3年总生存(OS)率分别为97.1%、81.9%,差异有统计学意义(P=0.041);3年无进展生存(PFS)率分别为69.1%、71.1%(P=0.546)。侵袭性FL组患者2年后出现PFS平台期。结论: 一线RCHOP方案治疗FL 3A级患者3年总生存率优于侵袭性FL,但两者的PFS差异无统计学意义,侵袭性FL患者治疗2年后出现PFS平台期。 |
关键词: 滤泡性淋巴瘤 RCHOP方案 临床特征 生存 |
DOI:10.12025/j.issn.1008-6358.2021.20210787 |
分类号:R551.2 |
基金项目:国家重大新药创制专项计划(2017ZX09304-021). |
|
Clinical efficiency of frontline RCHOP regimen in treatment of follicular lymphoma grade 3 patients with different histological subtypes |
CHEN Fei-fei1, AZIGULI Maihemaiti1,2, WEI Zheng1, CHENG Lu-ya1, WANG Wei-guang1, ZHUANG Jing-li1, YUAN Ling1, CHENG Zhi-xiang1, WANG Zhi-mei1, JI Li-li1, GE Xiao-wen3, LIU Peng1
|
1.Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China;2.Department of Lymphoma Medicine, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830000, Xinjiang Uygur Autonomous Region, China;3.Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
|
Abstract: |
Objective: To explore the clinical features and outcomes of follicular lymphoma (FL) grade 3 treated with frontline RCHOP regimen.Methods: 61 FL grade 3 patients treated with frontline RCHOP regimen between January 2009 and December 2019 were retrospectively analyzed. We divided them into FL grade 3A (n=42) and aggressive FL (n=19). Aggressive FL included grade 3A with an additional 3B component (n=2), grade 3B (n=8), and grade 3 with areas of diffuse large B cell lymphoma (n=9).Results: The baseline characteristics, including gender, age, serum β2 microglobulin and lactate dehydrogenase levels, Ann Arbor stage, B symptom and bone marrow involvement were similar between FL grade 3A and aggressive FL. After a median follow-up period of 40.2 months, the 3-year overall survival (OS) rate was 97.1% in FL grade 3A and 81.9% in aggressive FL, (P=0.041). The 3-year progression free survival (PFS) rate was 69.1% and 71.1%, respectively, (P=0.546). Patients of aggressive FL reached a plateau in the PFS curve after 2 years.Conclusions: The 3-year OS survival rate of the frontline RCHOP regimen in the treatment of FL3A patients was better than that of aggressive FL, but the PFS difference between the two was not statistically significant. PFS plateau appears after 2 years of treatment in aggressive FL patients. |
Key words: follicular lymphoma RCHOP clinical features survival |